晚期卵巢癌初次减灭术1-10mm残留与间歇减灭术无肉眼残留的生存比较
该回顾性研究纳入2010至2016年FIGO IIIC-IV期上皮性卵巢/输卵管/原发腹膜癌患者207例,比较初次减灭术(PDS)后1-10mm残留(59例)与间歇减灭术(IDS)后无肉眼残留(148例)的生存与并发症。两组进展/复发率相近,中位PFS无显著差异(16.2 vs 18.9个月,p=0.111),但PDS组中位OS更短(41.4 vs 52.4个月,p=0.022)且围手术期并发症更高。结论支持若预计PDS会留下毫米级残留,应优先选择IDS。
要点
- PDS组术中并发症16.9%、早期主要术后并发症28.8%,均显著高于IDS组的1.3%和2.0%。
- 两组中位PFS无显著差异(16.2 vs 18.9个月,p=0.111),但PDS组中位OS更短(41.4 vs 52.4个月,p=0.022)。
- 若预计PDS会留下1-10mm残留,IDS应作为首选治疗。
核心结论
- 在晚期上皮性卵巢癌中,PDS后1-10mm残留与IDS后无肉眼残留相比,PFS相似但OS更短且围手术期并发症更多,IDS应优先考虑。
研究设计与样本
- 回顾性纳入2010年1月至2016年12月FIGO IIIC-IV期上皮性卵巢/输卵管/原发腹膜癌患者207例,PDS组59例(残留1-10mm),IDS组148例(无肉眼残留),随访至少2年。
主要发现
- PDS组患者更年轻且手术复杂度评分更高。
- PDS组术中并发症发生率为16.9%,IDS组为1.3%;PDS组早期主要术后并发症发生率为28.8%,IDS组为2.0%(p<0.0001)。
- 中位随访56.4个月(范围59.2-65.4),全人群117例(56.5%)死于疾病;PDS组48例(81.4%)进展/复发,IDS组120例(81.1%)进展/复发。
- PDS组与IDS组中位PFS分别为16.2个月和18.9个月(p=0.111),中位OS分别为41.4个月和52.4个月(p=0.022)。
临床怎么用
- 对于预计PDS难以达到无肉眼残留、可能遗留1-10mm残留的晚期卵巢癌患者,应优先选择IDS以降低围手术期并发症并可能改善总生存。
局限性
- 本研究为回顾性设计,PDS组与IDS组在年龄和手术复杂度评分上存在差异,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare survival outcomes and peri-operative complications in patients with advanced ovarian cancer with 1-10 mm residual disease (RD) at primary debulking surgery (PDS) versus those achieving no gross residual disease (NGR) at interval debulking surgery (IDS). METHODS: Patients operated with the intent of complete cytoreduction for epithelial ovarian/fallopian tube/primary peritoneal cancer, FIGO stage IIIC-IV, RD 1-10 mm at PDS and NGR at IDS, between 01/2010 and 12/2016, were retrospectively included. All patients had at least 2-years of follow-up completed. RESULTS: 207 patients were included (59 PDS and 148 IDS). Patients in PDS group were younger and had a higher surgical complexity score. There was a higher rate of intra- and major early post-operative complications in the group of PDS vs IDS (16.9% vs 1.3% and 28.8% vs 2.0%, p < 0.0001 respectively). After a median follow up of 56.4 months (range 59.2-65.4), 117 (56.5%) patients died of disease in the whole population. Forty-eight (81.4%) patients had progression/recurrent disease in the PDS group and 120 (81.1%) in the IDS group. Median PFS was 16.2 months and 18.9 months for PDS and IDS group, respectively (p = 0.111). Median OS was 41.4 months and 52.4 months for PDS and IDS group, respectively (p = 0.022). CONCLUSIONS: IDS should be considered the preferred treatment in case millimetric residual disease is expected at PDS in view of the superimposable PFS and the reduced number of perioperative complications.
引用
- Ghirardi V, Moruzzi MC, Bizzarri N, et al. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis. Gynecol Oncol. 2020. PMID: 31952843. doi:10.1016/j.ygyno.2020.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。